Report Detail

Pharma & Healthcare Global Postmenopausal Osteoporosis Drugs Market Insights, Forecast to 2025

  • RnM2344618
  • |
  • 14 June, 2019
  • |
  • Global
  • |
  • 117 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global Postmenopausal Osteoporosis Drugs Market Insights, Forecast to 2025

Table of Contents

    1 Study Coverage

    • 1.1 Postmenopausal Osteoporosis Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Postmenopausal Osteoporosis Drugs Market Size Growth Rate by Product
      • 1.4.2 Antiresorptive Medications
      • 1.4.3 Anabolic Medications
    • 1.5 Market by End User
      • 1.5.1 Global Postmenopausal Osteoporosis Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Pharmacy
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Postmenopausal Osteoporosis Drugs Market Size
      • 2.1.1 Global Postmenopausal Osteoporosis Drugs Revenue 2014-2025
      • 2.1.2 Global Postmenopausal Osteoporosis Drugs Sales 2014-2025
    • 2.2 Postmenopausal Osteoporosis Drugs Growth Rate by Regions
      • 2.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Regions
      • 2.2.2 Global Postmenopausal Osteoporosis Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Postmenopausal Osteoporosis Drugs Sales by Manufacturers
      • 3.1.1 Postmenopausal Osteoporosis Drugs Sales by Manufacturers
      • 3.1.2 Postmenopausal Osteoporosis Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Postmenopausal Osteoporosis Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Postmenopausal Osteoporosis Drugs Revenue by Manufacturers
      • 3.2.1 Postmenopausal Osteoporosis Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Postmenopausal Osteoporosis Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Postmenopausal Osteoporosis Drugs Price by Manufacturers
    • 3.4 Postmenopausal Osteoporosis Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Postmenopausal Osteoporosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Postmenopausal Osteoporosis Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Postmenopausal Osteoporosis Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Postmenopausal Osteoporosis Drugs Sales by Product
    • 4.2 Global Postmenopausal Osteoporosis Drugs Revenue by Product
    • 4.3 Postmenopausal Osteoporosis Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Postmenopausal Osteoporosis Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Postmenopausal Osteoporosis Drugs by Countries
      • 6.1.1 North America Postmenopausal Osteoporosis Drugs Sales by Countries
      • 6.1.2 North America Postmenopausal Osteoporosis Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Postmenopausal Osteoporosis Drugs by Product
    • 6.3 North America Postmenopausal Osteoporosis Drugs by End User

    7 Europe

    • 7.1 Europe Postmenopausal Osteoporosis Drugs by Countries
      • 7.1.1 Europe Postmenopausal Osteoporosis Drugs Sales by Countries
      • 7.1.2 Europe Postmenopausal Osteoporosis Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Postmenopausal Osteoporosis Drugs by Product
    • 7.3 Europe Postmenopausal Osteoporosis Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Postmenopausal Osteoporosis Drugs by Countries
      • 8.1.1 Asia Pacific Postmenopausal Osteoporosis Drugs Sales by Countries
      • 8.1.2 Asia Pacific Postmenopausal Osteoporosis Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Postmenopausal Osteoporosis Drugs by Product
    • 8.3 Asia Pacific Postmenopausal Osteoporosis Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Postmenopausal Osteoporosis Drugs by Countries
      • 9.1.1 Central & South America Postmenopausal Osteoporosis Drugs Sales by Countries
      • 9.1.2 Central & South America Postmenopausal Osteoporosis Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Postmenopausal Osteoporosis Drugs by Product
    • 9.3 Central & South America Postmenopausal Osteoporosis Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Postmenopausal Osteoporosis Drugs by Countries
      • 10.1.1 Middle East and Africa Postmenopausal Osteoporosis Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Postmenopausal Osteoporosis Drugs by Product
    • 10.3 Middle East and Africa Postmenopausal Osteoporosis Drugs by End User

    11 Company Profiles

    • 11.1 Eli Lilly
      • 11.1.1 Eli Lilly Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Eli Lilly Postmenopausal Osteoporosis Drugs Products Offered
      • 11.1.5 Eli Lilly Recent Development
    • 11.2 Amgen
      • 11.2.1 Amgen Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Amgen Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Amgen Postmenopausal Osteoporosis Drugs Products Offered
      • 11.2.5 Amgen Recent Development
    • 11.3 Merck
      • 11.3.1 Merck Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck Postmenopausal Osteoporosis Drugs Products Offered
      • 11.3.5 Merck Recent Development
    • 11.4 Novartis
      • 11.4.1 Novartis Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novartis Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novartis Postmenopausal Osteoporosis Drugs Products Offered
      • 11.4.5 Novartis Recent Development
    • 11.5 Allergan
      • 11.5.1 Allergan Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Allergan Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Allergan Postmenopausal Osteoporosis Drugs Products Offered
      • 11.5.5 Allergan Recent Development
    • 11.6 Amgen Astellas Biopharm
      • 11.6.1 Amgen Astellas Biopharm Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Products Offered
      • 11.6.5 Amgen Astellas Biopharm Recent Development
    • 11.7 Deltanoid Pharmaceuticals
      • 11.7.1 Deltanoid Pharmaceuticals Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Products Offered
      • 11.7.5 Deltanoid Pharmaceuticals Recent Development
    • 11.8 Noven
      • 11.8.1 Noven Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Noven Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Noven Postmenopausal Osteoporosis Drugs Products Offered
      • 11.8.5 Noven Recent Development
    • 11.9 Novo Nordisk
      • 11.9.1 Novo Nordisk Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Novo Nordisk Postmenopausal Osteoporosis Drugs Products Offered
      • 11.9.5 Novo Nordisk Recent Development
    • 11.10 Osteologix
      • 11.10.1 Osteologix Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Osteologix Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Osteologix Postmenopausal Osteoporosis Drugs Products Offered
      • 11.10.5 Osteologix Recent Development
    • 11.11 Pfizer
    • 11.12 PhytoHealth
    • 11.13 Radius Health
    • 11.14 Tarsa Therapeutics

    12 Future Forecast

    • 12.1 Postmenopausal Osteoporosis Drugs Market Forecast by Regions
      • 12.1.1 Global Postmenopausal Osteoporosis Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Postmenopausal Osteoporosis Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Postmenopausal Osteoporosis Drugs Market Forecast by Product
      • 12.2.1 Global Postmenopausal Osteoporosis Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Postmenopausal Osteoporosis Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Postmenopausal Osteoporosis Drugs Market Forecast by End User
    • 12.4 North America Postmenopausal Osteoporosis Drugs Forecast
    • 12.5 Europe Postmenopausal Osteoporosis Drugs Forecast
    • 12.6 Asia Pacific Postmenopausal Osteoporosis Drugs Forecast
    • 12.7 Central & South America Postmenopausal Osteoporosis Drugs Forecast
    • 12.8 Middle East and Africa Postmenopausal Osteoporosis Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Postmenopausal Osteoporosis Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density.
      With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years.
      The global Postmenopausal Osteoporosis Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Postmenopausal Osteoporosis Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Postmenopausal Osteoporosis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Postmenopausal Osteoporosis Drugs in these regions.
      This research report categorizes the global Postmenopausal Osteoporosis Drugs market by top players/brands, region, type and end user. This report also studies the global Postmenopausal Osteoporosis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Eli Lilly
      Amgen
      Merck
      Novartis
      Allergan
      Amgen Astellas Biopharm
      Deltanoid Pharmaceuticals
      Noven
      Novo Nordisk
      Osteologix
      Pfizer
      PhytoHealth
      Radius Health
      Tarsa Therapeutics

      Market size by Product
      Antiresorptive Medications
      Anabolic Medications
      Market size by End User
      Hospital
      Pharmacy
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Postmenopausal Osteoporosis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Postmenopausal Osteoporosis Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Postmenopausal Osteoporosis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Postmenopausal Osteoporosis Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Postmenopausal Osteoporosis Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Postmenopausal Osteoporosis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Postmenopausal Osteoporosis Drugs . Industry analysis & Market Report on Postmenopausal Osteoporosis Drugs is a syndicated market report, published as Global Postmenopausal Osteoporosis Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Postmenopausal Osteoporosis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,099.86
      4,649.80
      6,199.73
      3,475.07
      5,212.61
      6,950.14
      423,395.70
      635,093.55
      846,791.40
      272,483.25
      408,724.88
      544,966.50
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report